AlloMap® Holder
AlloMap® The Future IMAGE of Heart Transplant Management
 

AlloMap is the only non-invasive gene expression test that helps physicians identify the absence* of heart transplant rejection

  • Provides Actionable Information: Quantifiable, objective, and reproducible test results
  • Offers Patient Comfort: Only requires a simple blood draw
  • Widely Adopted: Successfully used in over 21,000 cases to help physicians detect the absence* of heart transplant rejection at the time of testing in 7,000+ heart transplant patients
 

*Absence is defined here as the very low probability of moderate/severe acute cellular rejection as measured by the negative predictive value. AlloMap test results are only to be used in conjunction with standard clinical assessment.

AlloMap Intended Use:

AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment.

Indicated for use in patients:15 years of age or older and at least 2 months (≥ 55 days) since transplantation.